A PHASE I/IIA, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AZD0022 MONOTHERAPY AND IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH TUMOURS HARBOURING A KRASG12D MUTATION (ALAFOSS-01)

Registry ID

D7080C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2025-06-16

Last update

2024-11-27

Conditions

• TUMOR

Related clinical trials

• A PILOT STUDY OF INTRATHECAL TOPOTECAN AND MAINTENANCE CHEMOTHERAPY IN THE POST-CONSOLIDATION SETTING FOR THE TREATMENT OF HIGH-RISK EMBRYONAL CENTRAL NERVOUS SYSTEM TUMOURS IN CHILDREN LESS THAN 6 YEARS OF AGE
• PERFORMANCE OF 18F-FLUOROCHOLINE POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY IN PATIENTS WITH 18F-FLUOROCHOLINE-AVID LESIONS: A BASKET TRIAL
• A PHASE II, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB DERUXTECAN (T-DXD, DS-8201A) FOR THE TREATMENT OF SELECTED HER2-EXPRESSING TUMORS (DESTINY PANTUMOR02)

View on source registry